Low-risk prostate cancer: active surveillance or treatment

A recommendation for active surveillance after a low-risk prostate cancer diagnosis can feel surprising: cancer has been identified, but an operation is not proposed immediately. In an appropriate situation, surveillance is a structured pathway with examinations and predefined reasons to reconsider treatment. It differs both from abandoning care and from simply waiting for symptoms to develop.

Confirm what “low risk” means in this case

The assessment draws on biopsy pathology, grade group, PSA, local extent and other clinical information. A small lesion or an absence of pain does not establish low risk on its own. For another opinion, provide the full biopsy report with the distribution of samples, dated PSA results and available MRI images and reports.

If different biopsy cores have different findings, do not send only the most favourable line. Ask the specialist to explain the overall assessment and remaining uncertainty. A pathology review or additional investigation may sometimes be discussed, but the need should be defined by the clinician rather than anticipated through self-ordered tests.

Understand the purpose of active surveillance

Active surveillance uses an agreed monitoring programme to identify changes that could make treatment appropriate. NCI distinguishes it from watchful waiting, which focuses more on treating symptoms when they arise. The choice takes account of the cancer, general health, life expectancy and the person’s preferences. NCI: Prostate Cancer Treatment.

Ask which examinations apply to you, who will interpret them and what changes would trigger a new discussion. A programme should be more specific than “have a PSA test occasionally.” The timing of blood tests, MRI or repeat biopsy nevertheless belongs to the treating team rather than to a universal schedule copied from a website.

Compare the benefits and burdens of both routes

For a suitable patient, surveillance can postpone or avoid unnecessary immediate intervention. It also requires continuing clinical contact and willingness to attend the agreed investigations. Some people experience substantial anxiety while living with an untreated diagnosis. That is a valid part of the conversation, not evidence that the patient has failed to understand the approach.

Surgery and radiotherapy require their own assessment of expected benefit and effects on urinary, sexual and other functions. Ask which risk the team aims to reduce through immediate treatment and why that benefit is expected to outweigh its burdens. Neither “removing it must always be safer” nor “avoiding treatment must always be safer” is an adequate basis for an individual decision.

Arrange monitoring where you live

If the opinion is obtained in Turkey and monitoring will take place at home, identify a local urologist or oncologist before relying on that plan. Ask which laboratories and imaging formats can be used for comparison, how results will be transferred and who will identify a need for an unscheduled review. Another international trip should not be the only route to clarification of an important change.

Request a written baseline and monitoring plan. If the responsible doctor changes, transfer the complete sequence of previous results so the new clinician can assess the trend. Comparing isolated results from different times without the clinical context can increase anxiety without making the decision clearer.

Use a second opinion to resolve specific uncertainty

Ask whether surveillance is appropriate for you, what missing information might alter that conclusion, which alternatives are reasonable and what would prompt treatment. If another doctor recommends an operation, request the specific reason for the difference. It might concern pathology, risk interpretation, follow-up feasibility or a personal priority that one consultation did not capture.

The guides to an oncology second opinion and comparing treatment proposals can help organize the answers. An agreed surveillance plan does not promise that the cancer will never change. It establishes a responsible clinician, an understandable monitoring process and a willingness to reconsider the decision when new evidence appears.